NSE: JUBLINGREA · 30 October 2026
- Jubilant Ingrevia has fallen 11.69% over 3 trading sessions; today's move is -1.66%.
- The board approved financial results for the quarter and half year ended September 30, 2026, reporting total quarterly revenue of ₹1,394 crore, reflecting a 24% year-on-year growth. Total EBITDA reached ₹221 crore, representing a 51% increase year-on-year, while PAT after exceptional items rose 61% year-on-year to ₹111 crore.
- Trading volume was 1.47 times the 20-day average daily volume.
Jubilant Ingrevia share price: 11.69% decline over 3 trading sessions
Jubilant Ingrevia Ltd. shares fell 1.66% on Thursday, trading between a day's low of ₹544.15 and a high of ₹568.15 before closing at ₹558.40.
The broader market saw positive momentum with the Nifty rising 0.51%, whereas sector performance showed pressure as the Nifty Metal benchmark declined 0.54%. Jubilant Ingrevia's downward price action aligns with a broader short-term pullback, following a 5-day return of -7.23% and a 20-day return of -14.51%.
Company disclosures provide important fundamental context regarding the firm's trajectory, even if recent results are not the sole direct trigger for today's intraday price move. On October 27, 2026, the company reported its financial results for the quarter ended September 30, 2026, posting an all-time high quarterly revenue of ₹1,394 crore up 24% year-on-year, and an EBITDA of ₹221 crore up 51% year-on-year. Additionally, a bulk deal filing showed East Bridge Capital Master Fund I Limited acquiring 921,668 shares at ₹601.75 on October 28, 2026, reflecting active institutional interest at higher levels.
6.99 lakh shares traded by 30 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 4.77 lakh shares (1.47 times). The five-day average daily volume was 12.64 lakh shares. Separately, the NSE report for 29 October 2026 showed 6.01 lakh shares delivered, representing 55.14% of that day’s traded volume. The same report recorded 48,072 trades.
The stock declined 1.66% amid heavier-than-average volume, extending a broader short-term correction that includes a 20-day return of -14.51%. While recent Q2 earnings announcements and institutional bulk deals highlight strong fundamentals, immediate price action reflects ongoing selling pressure.
Latest Company Developments
The board approved financial results for the quarter and half year ended September 30, 2026, reporting total quarterly revenue of ₹1,394 crore, reflecting a 24% year-on-year growth. Total EBITDA reached ₹221 crore, representing a 51% increase year-on-year, while PAT after exceptional items rose 61% year-on-year to ₹111 crore.
Demonstrates robust operational execution and record revenue supported by strong performance across specialty chemicals, nutrition, and chemical intermediate segments.
Management announced an agreement to acquire a 40% stake in ZettaOne Technologies Limited with an investment of ₹189.2 crore. This transaction marks the company's entry into the Electronics Development and Manufacturing Services (EDMS) space to offer integrated value propositions in the electronics and semiconductor sectors.
Expands the company's addressable market into high-growth electronics and semiconductor ecosystems alongside existing chemical operations.
Ms. Vinita Koul tendered her resignation as Senior Vice President and Head HR, effective from the close of business hours on November 6, 2026, to pursue other professional interests. The company noted that transition plans are underway to ensure operational continuity.
Changes in senior human resources leadership require monitoring for smooth organizational transition during periods of rapid operational expansion.
a press release dated October 27, 2026, titled "Press Release and Presentation on the financials and operational performance of the Company for the quarter and half year ended September 30, 2026".
Grant of Stock Options under Jubilant Ingrevia Employees Stock Option Scheme 2021.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 22.59% on 30 September 2026. This compares with 22.39% on 30 June 2026, a change of +0.20 percentage points.
The filing reported 26 MF/UTI holders.
Research & Brokerage Views
Retained a 'Buy' rating citing expectations of sharp earnings growth ahead.
Maintained a 'Buy' recommendation with a target price of ₹649, betting on underlying earnings inflection.
Historical Bulk / Block Deals
What to Watch Next
- Execution progress and integration timeline regarding the 40% stake acquisition in ZettaOne Technologies
- Volume trends relative to the 20-day average volume of 1.47x to gauge institutional accumulation or distribution
- Delivery percentage stability compared to the recent 55.14% level
- Commissioning progress on the new Multi-Purpose Plant targeted by year-end for CDMO and Fine Chemicals expansion
Other Dated Coverage
- Jubilant Ingrevia Share Price Today: Falls 10.20% in 2 Trading Sessions | 29 October 2026 — 29 October 2026
- Jubilant Ingrevia Share Price Falls 8.02% Intraday, Closes 6.13% Lower | 28 October 2026 — 28 October 2026
- Jubilant Ingrevia Share Price Jumps 8.65% Intraday, Closes 4.35% Higher | 27 October 2026 — 27 October 2026
More Jubilant Ingrevia news and dated analysis →
Frequently Asked Questions
What is the latest Jubilant Ingrevia company news?
The board approved financial results for the quarter and half year ended September 30, 2026, reporting total quarterly revenue of ₹1,394 crore, reflecting a 24% year-on-year growth. Total EBITDA reached ₹221 crore, representing a 51% increase year-on-year, while PAT after exceptional items rose 61% year-on-year to ₹111 crore.
How strong was Jubilant Ingrevia’s trading volume?
6.99 lakh shares traded, 1.47 times the 20-day average daily volume. The price and volume data are dated 30 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.